SEC Form 4 · accession 0001144204-16-108656
Neurotrope, Inc. · NTRP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paula T Trzepacz
Officer — See Remarks
Period of report
Jun 15, 2016
Accepted (ET)
Jun 17, 2016 · 11:04 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001513856
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $0.60 | Jun 15, 2016 | A | 250,000 | A | — | Jun 15, 2026 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1These securities were issued in connection with the Reporting Person's appointment as Executive Vice President and Chief Medical Officer of the issuer's wholly-owned subsidiary.
- F2The stock options shall vest in equal installments as follows: 25% shall vest immediately upon the date of grant and 25% shall vest on each of the first, second and third anniversaries of the date of grant (assuming continued service through such date).
Remarks
Title: EVP and CMO, Neurotrope BioScience, Inc.